Kexing Biopharm and IQVIA Team Up for Global Expansion in Healthcare

Kexing Biopharm Forms Strategic Alliance with IQVIA for Global Growth

Kexing Biopharm (688136.SH), a dynamic force in the biopharmaceutical industry, has officially launched a strategic partnership with IQVIA (NYSE:IQV), a titan in clinical research services and healthcare analytics. This alliance aims to fast-track the global development and commercial rollout of Kexing's innovative drugs and biosimilars, with a primary focus on entering European and other highly regulated international markets.

Over the past several years, Kexing Biopharm has made remarkable strides toward international expansion by establishing a distinctive globalization platform that combines cutting-edge research and development capabilities with agile commercial strategies. The company has launched several high-quality pharmaceutical products into the overseas markets, achieving swift regulatory approvals. One notable success is the rapid approval of nab-paclitaxel, which has been introduced in major jurisdictions worldwide.

Going forward, Kexing is set to intensify its research pipeline, concentrating on therapeutic areas, including antiviral therapies, cancer treatments, immunosuppressants, and metabolic disease management. The collaboration with IQVIA will leverage its extensive expertise in global clinical trial designs, regulatory strategies, and data insights.

By coupling Kexing's innovative product pipeline with IQVIA’s robust operational network, the partnership aspires to enhance trial efficiencies and expedite access to international markets, thereby significantly strengthening Kexing's capabilities in global drug development.

During the signing ceremony, Brian Mi, President of IQVIA Asia Pacific, emphasized Kexing's swift progress in commercializing products abroad, stating that this partnership would unlock fresh possibilities for both entities. Yanqing Zhao, CEO of Kexing, highlighted that IQVIA's wealth of global clinical data, patient insights, and regulatory expertise would be fundamental in fine-tuning Kexing's development strategies, boosting success prospects, and shortening global registration timelines.

Kexing Biopharm is not just any biopharmaceutical enterprise; it is a pioneer dedicated to the research, production, and marketing of recombinant protein therapies and micro-ecological products. Its emphasis on devising cutting-edge biotechnology platforms encompasses various therapeutic fields, including antiviral, oncology, autoimmune, and metabolic disorders. The company stands firm on an “innovation and internationalization” development model, exploring biotechnology's vast applications across the broader health sector.

This strategic alliance serves as a testament to Kexing Biopharm's unwavering commitment to global expansion through scientific rigor, effective execution, and strategic collaborations. As the company navigates this promising new chapter, it remains resolved to deepen its global partnerships to introduce a wealth of high-quality, Chinese pharmaceutical innovations to patients worldwide.

In summary, the partnership between Kexing Biopharm and IQVIA marks a significant milestone in the biopharmaceutical landscape, aiming to redefine how innovative therapies are developed and delivered globally. With a shared vision of improving health outcomes through advanced biopharmaceutical solutions, both companies are well-poised to make an impactful difference on the world stage.